Monoclonal antibody · Agonist of TRAIL-R1 (tumor necrosis factor-related apoptosis-inducing ligand receptor 1) (TNFRSF10A) · developed by Human Genome Sciences Inc., a GSK Company
Mapatumumab is a fully human agonistic monoclonal antibody that binds and activates the TRAIL-R1 cell surface receptor, inducing apoptosis in malignant cells. It is studied in hepatocellular carcinoma.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.